ClinicalTrials.gg
Not yet recruitingNCT07483684Updated Mar 19, 2026

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

A Phase 3 interventional study of TQB2102 Injection and Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets in HER2 IHC3+ Advanced Colorectal Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Not yet recruiting at 48 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited — 6 open to participants now, 7 under way, 2 of them phase 3. Colorectal Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
4th of 13
142 · median 72
Started
2026
with 2 others
Phase 3
2 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 3, and was the 11th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a Phase III, randomized, open-label, active-controlled, multicenter study designed to evaluate the efficacy and safety of Injection TQB2102 compared with investigator's choice of treatment in subjects with Human Epidermal Growth Factor Receptor 2 (HER2) ImmunoHistoChemistry score 3 (IHC3+) advanced colorectal cancer who have failed prior treatment with oxaliplatin, irinotecan, and fluoropyrimidine-based regimens.

The primary endpoint of this study is progression-free survival (PFS) as assessed by an Independent Review Committee (IRC). The key secondary endpoint is overall survival (OS). Other secondary endpoints include investigator-assessed PFS, objective response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), safety, and quality of life scores.

Approximately 142 subjects are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the experimental group or the control group.

03

Conditions studied

  • HER2 IHC3+ Advanced Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject voluntarily participates in this study, signs the form, and has good compliance.
  • Aged 18 to 75 years old (calculated as of the date of signing the informed consent form).
  • Subjects with or cytologically confirmed advanced colorectal cancer.
  • The subject has confirmed IHC3+ status in tumor tissue, as determined by the central laboratory designated by the sponsor.
  • The subject must provide a sufficient quantity of qualified tumor specimens (fresh or archived samples collected within the past 3 years from primary or lesions) for central laboratory testing of HER2 status.
  • Advanced colorectal cancer that has progressed on or been intolerant to at least 2 prior lines of standard therapy (defined as disease progression or intolerable toxicity during or within 3 months after the last standard therapy).
  • (ECOG) performance status of 0 to 1.
  • Expected survival of greater than 12 weeks.
  • Presence of at least one as confirmed by 1.1 criteria.
  • Laboratory tests must meet criteria
  • Women of must agree to use effective during the study and for 6 months after the study ends, and have a negative serum or urine pregnancy test within 7 days prior to study entry. Men must agree to use effective contraception during the study and for 6 months after the study ends.

Exclusion criteria

Exclusion Criteria:

  • A history of other malignant tumors within 3 years prior to the first dose, or concurrent malignant tumors at screening. Subjects are eligible for enrollment if they meet one of the following two conditions:

    • Other malignant tumors treated with curative intent via a single surgical procedure, with disease-free survival (DFS) maintained for 5 consecutive years;
    • A history of cured carcinoma in situ of the cervix, non-melanoma skin cancer, or superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)].
  • Presence of diseases that affect intravenous injection or venous blood collection, or factors that impair oral drug administration (e.g., dysphagia, chronic diarrhea, intestinal obstruction, etc.).
  • Failure of adverse reactions from prior treatments to resolve to ≤ Grade 1 per v5.0, with the following exceptions: Grade 2 alopecia, Grade 2 peripheral neurotoxicity, Grade 2 anemia, non- and asymptomatic laboratory abnormalities, type 1 diabetes mellitus and hypothyroidism stabilized with hormone replacement therapy, and other toxicities judged by the investigator to pose no safety risks.
  • Receipt of major surgical treatment, significant traumatic injury within 4 weeks prior to the first dose; or planned major surgery during the study period (excluding surgeries specified in the protocol); or presence of unhealed wounds or fractures for a prolonged period.
  • Clinically significant tumor bleeding or perforation within 1 month prior to the first dose; or any bleeding event ≥ Grade 3 per CTCAE v5.0; or subjects with bleeding or coagulation disorders receiving warfarin, aspirin, or other antiplatelet agents (excluding maintenance doses: aspirin ≤ 100 mg/day, clopidogrel ≤ 75 mg/day); or subjects with a history or signs of bleeding deemed ineligible by the investigator.
  • A history of thrombotic or embolic events within 6 months prior to the first dose, such as cerebrovascular accident (including , cerebral hemorrhage, cerebral infarction), deep vein thrombosis (DVT) [excluding subjects with isolated calf vein thrombosis ≤ 7 mm in diameter, ≤ 5 cm in length, not involving ≥ 2 veins, and assessed by the investigator as having no risk of thrombus progression], and pulmonary embolism, etc.
  • Presence of major cardiovascular diseases.
  • A history of decompensated liver cirrhosis or hepatic encephalopathy.
  • Subjects with active chronic or active chronic . Subjects positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening must undergo additional testing for Hepatitis B Virus (HBV) DNA titer or HCV RNA quantification.
  • Active syphilis infection requiring treatment.
  • A history of (non-infectious) pneumonitis/interstitial lung disease requiring therapy; or current diagnosis of non-infectious pneumonitis/interstitial lung disease; or hospitalization for any active infection or receipt of therapeutic antibiotics within 4 weeks prior to the start of study treatment, including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • Active or uncontrolled severe infection (≥ Grade 2 infection per CTCAE v5.0).
  • A history of psychoactive substance abuse with inability to abstain, or presence of mental disorders.
  • A history of immunodeficiency, including positivity, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
  • Tumor-related symptoms and treatments.
  • Known or allergic reaction to any study drug or its .
  • Prior receipt of anti- antibody-drug conjugate (ADC) therapy.
  • Receipt of any anticancer therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) or any other drug therapy within 4 weeks or 5 half-lives prior to the first dose of this study, whichever is shorter.
  • Pregnant or lactating subjects.
  • Vaccination with within 28 days prior to the start of study treatment, or inactivated vaccines within 7 days prior; or planned vaccination during the study period.
  • Any other condition judged by the investigator to pose a serious risk to subject safety or interfere with the subject's completion of the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    TQB2102 Injection

    TQB2102 Injection, 21days as a treatment cycle, administered on Day 1 of each cycle

    Drug: TQB2102 Injection

  • Experimental
    Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets

    TAS-102 tablets: Oral administration, 35 mg/m² (maximum single dose: 80 mg), twice daily on Days 1-5 and Days 8-12. Each treatment cycle is 4 weeks (Q4W). Fruquintinib: Oral administration, 5 mg once daily (QD), on Days 1-21 of each cycle. Each treatment cycle is 4 weeks (Q4W). Regorafenib tablets: Oral administration, 160 mg once daily (QD), on Days 1-21 of each cycle. Each treatment cycle is 4 weeks (Q4W).

    Drug: Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets

Interventions

  • TQB2102 Injection is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug.

  • DrugTrifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets

    TAS-102 Tablets: Antimetabolite antitumor drug; trifluridine inhibits DNA synthesis by incorporating into tumor cell DNA, while tipiracil increases trifluridine bioavailability by inhibiting its degradation. Fruquintinib Tablets: Oral small-molecule VEGFR inhibitor; blocks VEGFR 1/2/3 signaling to inhibit tumor angiogenesis, cutting off tumor nutrient and oxygen supply. Regorafenib Tablets: Multikinase inhibitor; targets VEGFR, PDGFR, Fibroblast Growth Factor Receptor (FGFR), and Raf kinases to inhibit tumor angiogenesis, cell proliferation, and metastasis.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) assessed by IRC based on RECIST v1.1

    To evaluate the Progression-Free Survival (PFS) assessed by IRC of TQB2102 Injection compared to investigator-selected chemotherapy in subjects.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months

Secondary outcomes

  1. Overall Survival (OS)

    To evaluate the Overall Survival (OS) of TQB2102 Injection compared to investigator-selected chemotherapy in subjects.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months

  2. Objective Response Rate (ORR)

    To evaluate the Objective Response Rate (ORR) of TQB2102 Injection compared to investigator-selected chemotherapy in subjects.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months

  3. Duration of Response (DOR)

    To evaluate the Duration of Response (DOR) of TQB2102 Injection compared to investigator-selected chemotherapy in subjects.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months

  4. Disease Control Rate (DCR)

    To evaluate the Disease Control Rate (DCR), of TQB2102 Injection compared to investigator-selected chemotherapy in subjects

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months

  5. Time to Response (TTR) (assessed by both IRC and investigators)

    To evaluate the Time to Response (TTR) (assessed by both IRC and investigators), of TQB2102 Injection compared to investigator-selected chemotherapy in subjects.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months

  6. Investigator-assessed PFS

    To evaluate the investigator-assessed PFS of TQB2102 Injection compared to investigator-selected chemotherapy in subjects.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months

  7. Survival rates at 3 months, 6 months, 9 months, and 12 months

    To evaluate the Survival rates at 3 months, 6 months, 9 months, and 12 months of TQB2102 Injection compared to investigator-selected chemotherapy in subjects.

    Time frame: Baseline, 3, 6, 9, 12 months

  8. Quality of life scores at 3 months, 6 months, 9 months, and 12 months

    To evaluate the quality of life scores at 3 months, 6 months, 9 months, and 12 months of TQB2102 Injection compared to investigator-selected chemotherapy in subjects. Higher scores indicate more severe conditions.

    Time frame: Baseline, 3, 6, 9, 12 months

  9. The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 50 months

  10. Pharmacokinetic (PK)-Ctrough

    Exploration of the Pharmacokinetic Characteristics of TQB2102 Injection Using Trough Concentrations.

    Time frame: Within 1 hour prior to the start of infusion for Cycle 1, Cycle 4, Cycle 7, and Cycle 12 (each cycle is 21 days)

  11. Immunogenicity of TQB2102: ADA incidence

    Exploration of Anti-Drug Antibody (ADA) Characteristics for TQB2102 Injection.

    Time frame: Within 1 hour prior to the start of infusion for Cycle 1, 4, 7, and 12, and 90 days after last infusion. (Each cycle is 21 days)

07

Study locations

48 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Aug 2027, 17 months later.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 17 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 19, 2026
StartEst.
Mar 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2028
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07483684
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Mar 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 19, 2026

Study contacts

Ruihua Xu, Doctor
Contact
xurh@syscc.org.cn
020-87343468
Hui Guo, Doctor
Contact
guohui@xjtufh.edu.cn
029-87678864

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

Start the discussion